MedTech News
.................... by Andrew Celentano
3D-printed brain models could improve medical research and training
University of Missouri researchers are developing new ways to better simulate the complex nature of human brain tissue.
Gamma-synced brain stimulation can nudge people to behave less selfishly
Stimulating two brain areas, nudging them to collectively fire in the same way, increases a person’s ability to behave altruistically.
Scientists create ‘smart underwear’ to measure human flatulence
Scientists at the University of Maryland have created Smart Underwear, the first wearable device designed to measure human flatulence.
TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial
ANDOVER, Mass., Feb. 9, 2026 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial.
AI model can accelerate antibody drug production
Researchers detail a machine learning model that dramatically accelerates the manufacturing timeline of monoclonal antibodies.
AI algorithm enables tracking of brainstem’s vital white matter pathways
Research reveals distinct patterns of structural changes in patients with Parkinson’s disease, multiple sclerosis, and traumatic brain injury.
Simple patch can make medications safer and more effective
Researchers working alongside Australian diagnostics company Nutromics developed a minimally invasive patch that tracks the antibiotic in patients every five minutes.
Neurophet Secures FDA 510(k) Clearance for “Neurophet AQUA AD Plus,” Marking Its Third U.S. Regulatory Milestone
SEOUL, South Korea, Feb. 6, 2026 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that its software solution, Neurophet AQUA AD Plus, a comprehensive neuroimaging analysis solution for clinical evaluation related to Alzheimer’s disease, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).